Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
PhenomeX, formerly known as Berkeley Lights, is a biotechnology company founded in 2011 and based in Emeryville, California. We specialize in developing cell-based products and single-cell analysis technologies, offering a range of optofluidic systems and proteomic barcoding technologies. These innovations enable rapid cell screening and detailed phenotypic and genotypic analysis, with applications in antibody discovery, cell line development, and T cell profiling.
Since its inception, PhenomeX has made significant strides in the biotechnology sector, raising a total of $223.68 million in funding. The company's advanced technologies have positioned it as a notable player in the field of single-cell analysis and cell-based product development.
As of now, we have not found any concrete news or official announcements regarding PhenomeX's IPO prospects. Without verified information, it's not possible to make any predictions about the company's plans to go public or potential IPO timing.
It's worth noting that PhenomeX was acquired by Novo Nordisk in December 2018, which may impact any future decisions regarding an initial public offering. However, the biotechnology sector has seen increased interest from investors in recent years, particularly for companies developing innovative technologies in cell analysis and therapeutics.
Investors interested in PhenomeX or similar companies in the biotechnology sector should continue to monitor official company announcements and industry news for any updates on potential IPO plans or other significant developments.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While PhenomeX's IPO prospects remain uncertain, investors eager to gain exposure to innovative life sciences companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the biotechnology sector. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging industry pioneers like PhenomeX before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
